Answers are grounded in this paper and cite their sources.
Review reveals advances in engineered fibrinolytic agents for acute myocardial infarction, suggesting improved drug design enhances reperfusion while reducing bleeding complications.
F.J. Van de Werf; The ideal fibrinolytic: can drug design improve clinical results?, European Heart Journal, Volume 20, Issue 20, 1 October 1999, Pages 1452–145
No takes yet. Share an insight, caveat, or question.
Frans Van de Werf (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: